Concord Drugs Ltd
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on
approved formulations
- Market Cap ₹ 51.4 Cr.
- Current Price ₹ 51.4
- High / Low ₹ 53.0 / 26.1
- Stock P/E 151
- Book Value ₹ 34.1
- Dividend Yield 0.00 %
- ROCE 5.30 %
- ROE 1.00 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 1.86% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
58.96 | 52.08 | 44.92 | 45.25 | |
53.37 | 47.51 | 40.88 | 41.10 | |
Operating Profit | 5.59 | 4.57 | 4.04 | 4.15 |
OPM % | 9.48% | 8.77% | 8.99% | 9.17% |
0.10 | 0.01 | 0.01 | 0.00 | |
Interest | 1.68 | 1.71 | 1.87 | 2.03 |
Depreciation | 1.76 | 1.63 | 1.56 | 1.43 |
Profit before tax | 2.25 | 1.24 | 0.62 | 0.69 |
Tax % | 28.89% | 20.97% | 25.81% | 50.72% |
1.59 | 0.99 | 0.47 | 0.34 | |
EPS in Rs | 1.82 | 1.06 | 0.47 | 0.34 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -8% |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -40% |
TTM: | -28% |
Stock Price CAGR | |
---|---|
10 Years: | -3% |
5 Years: | 25% |
3 Years: | 24% |
1 Year: | 30% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 2% |
Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Equity Capital | 8.74 | 9.32 | 10.00 | 10.00 |
Reserves | 19.62 | 22.38 | 23.82 | 24.11 |
16.43 | 16.96 | 17.52 | 17.19 | |
11.66 | 9.57 | 7.47 | 13.84 | |
Total Liabilities | 56.45 | 58.23 | 58.81 | 65.14 |
13.97 | 12.92 | 11.68 | 12.21 | |
CWIP | 0.55 | 0.92 | 1.63 | 2.00 |
Investments | 0.00 | 0.89 | 0.84 | 0.80 |
41.93 | 43.50 | 44.66 | 50.13 | |
Total Assets | 56.45 | 58.23 | 58.81 | 65.14 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
0.77 | 1.66 | 0.79 | 3.72 | |
-2.44 | -2.27 | -1.01 | -2.32 | |
1.68 | 0.62 | 0.28 | -1.43 | |
Net Cash Flow | 0.01 | 0.02 | 0.07 | -0.02 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Debtor Days | 141.52 | 110.80 | 161.13 | 109.70 |
Inventory Days | 151.64 | 178.58 | 251.53 | 261.81 |
Days Payable | 62.25 | 46.92 | 37.75 | 78.95 |
Cash Conversion Cycle | 230.90 | 242.47 | 374.91 | 292.56 |
Working Capital Days | 198.84 | 252.16 | 317.30 | 243.76 |
ROCE % | 6.31% | 4.98% | 5.30% |
Documents
Announcements
-
Clarification Letter Sought From BSE
13h - Company clarifies share price movement is market-driven, complies with SEBI disclosure norms.
-
Clarification sought from Concord Drugs Ltd
14h - Exchange has sought clarification from Concord Drugs Ltd on July 2, 2025, with reference to Movement in Price
-
Board Meeting Intimation for Issue Of Shares Through Preferential Allotment
2d - Board meeting on July 3, 2025, to consider capital increase and preferential fund raising.
-
Board Meeting Outcome for Outcome Of Board Meeting
27 Jun - Concord Drugs temporarily puts on hold preferential share issue and authorized capital increase proposal.
-
Closure of Trading Window
26 Jun - Trading window closed from July 1, 2025 till 48 hours after June quarter results announcement.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Product Portfolio:[1]
a) Pharmaceutical Ready to fill Pellets
b) Multiple Unit Pellet System (MUPS)
c) Tissue Bio Adhesive
d) Injectables (Small Volume Parenterals)
e) Oral Solid Dosages (Tablets & Capsules)
f) Liquid Orals (Syrups & Suspensions)
g) Dry Syrup (Powder)